{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:46:05Z","timestamp":1792169165607,"version":"4.4.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Characterising somatic mutation profiles in human breast cancer (HBC) is essential for understanding tumour progression and guiding therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed genomic and transcriptomic analyses to profile the mutational landscape of HBC. In addition to our primary analysis of HBC, we conducted comparative genomic analyses to evaluate the extent to which these mutational processes are recapitulated in canine mammary tumour (CMT), a widely proposed translational model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>APOBEC3 (A3)-associated mutations were extensive in HBC but largely absent in CMT, likely due to structural differences in A3 proteins and lower basal expression. Transcriptomic stratification of HBC by A3 activity uncovered that tumours with A3 activity showed a strong association with the PAM50-HER2-Enriched (HER2E) subtype, and FGFR4 was significantly correlated with the expression and enzymatic function of APOBEC3A\/B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate that CMT is an unsuitable model for A3-mediated mutagenesis, emphasising the need to consider the limitations of cross-species mutational modelling in comparative oncology. Moreover, this study identifies a potential regulatory association between FGFR4 and A3, offering insights into the underlying mechanisms of A3-driven mutagenesis and suggesting that the FGFR4-A3 activity could be considered alongside other molecular biomarkers for the classification of the HER2E subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03517-8","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:58:52Z","timestamp":1785153532000},"page":"1483-1498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGFR4-associated APOBEC3 mutagenesis characterizes HER2-enriched subtype of human breast cancer"],"prefix":"10.1038","volume":"135","author":[{"given":"Ju-Yul","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Yi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Reum","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-3577","authenticated-orcid":false,"given":"Je-Yoel","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"3517_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10.","journal-title":"CA Cancer J Clin"},{"key":"3517_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng L-W, Ding Y, Chen Y-F, Cai Y-W, Wang L-P, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10:49.","journal-title":"Signal Transduct Target Ther"},{"key":"3517_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47\u201354.","journal-title":"Nature"},{"key":"3517_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101.","journal-title":"Nature"},{"key":"3517_CR5","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3517_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4048\/jbc.2023.26.e4","volume":"26","author":"JY Kwon","year":"2023","unstructured":"Kwon JY, Moskwa N, Kang W, Fan TM, Lee C. Canine as a comparative and translational model for human mammary tumor. J Breast Cancer. 2023;26:1.","journal-title":"J Breast Cancer"},{"key":"3517_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12272-024-01524-y","volume":"48","author":"ZA Bhutta","year":"2025","unstructured":"Bhutta ZA, Choi K-C. Canine mammary tumors as a promising adjunct preclinical model for human breast cancer research: similarities, opportunities, and challenges. Arch Pharmacal Res. 2025;48:43\u201361.","journal-title":"Arch Pharmacal Res"},{"key":"3517_CR8","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.3390\/ijms25052891","volume":"25","author":"Nosalova","year":"2024","unstructured":"Nosalova, Huniadi N, Hor\u0148\u00e1kov\u00e1 M, Valen\u010d\u00e1kov\u00e1 A, Hor\u0148\u00e1k S, Nagoos K, et al. Canine mammary tumors: classification, biomarkers, traditional and personalized therapies. Int J Mol Sci. 2024;25:2891.","journal-title":"Int J Mol Sci"},{"key":"3517_CR9","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.3390\/cancers11122006","volume":"11","author":"K-H Lee","year":"2019","unstructured":"Lee K-H, Hwang H-J, Noh HJ, Shin T-J, Cho J-Y. Somatic mutation of PIK3CA (H1047R) is a common driver mutation hotspot in canine mammary tumors as well as human breast cancers. Cancers. 2019;11:2006.","journal-title":"Cancers"},{"key":"3517_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-019-0149-8","volume":"6","author":"K-K Kim","year":"2019","unstructured":"Kim K-K, Seung B-J, Kim D, Park H-M, Lee S, Song D-W, et al. Whole-exome and whole-transcriptome sequencing of canine mammary gland tumors. Sci Data. 2019;6:147.","journal-title":"Sci Data"},{"key":"3517_CR11","unstructured":"Li H: Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv preprint arXiv:13033997 2013."},{"key":"3517_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab007","volume":"10","author":"JK Bonfield","year":"2021","unstructured":"Bonfield JK, Marshall J, Danecek P, Li H, Ohan V, Whitwham A, et al. HTSlib: C library for reading\/writing high-throughput sequencing data. Gigascience. 2021;10:giab007.","journal-title":"Gigascience"},{"key":"3517_CR13","unstructured":"Picard Toolkit [https:\/\/broadinstitute.github.io\/picard\/]."},{"key":"3517_CR14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297\u2013303.","journal-title":"Genome Res"},{"key":"3517_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, K\u00e4llberg M, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat methods. 2018;15:591\u20134.","journal-title":"Nat methods"},{"key":"3517_CR16","unstructured":"Kandoth C, Gao J, Mattioni M, Struck A, Boursin Y. mskcc\/vcf2maf: vcf2maf v1.6.16. GitHub; 2020. Available from: https:\/\/github.com\/mskcc\/vcf2maf."},{"key":"3517_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-019-6041-2","volume":"20","author":"EN Bergstrom","year":"2019","unstructured":"Bergstrom EN, Huang MN, Mahto U, Barnes M, Stratton MR, Rozen SG, et al. SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. BMC Genom. 2019;20:1\u201312.","journal-title":"BMC Genom"},{"key":"3517_CR18","doi-asserted-by":"crossref","unstructured":"Islam SA, D\u00edaz-Gay M, Wu Y, Barnes M, Vangara R, Bergstrom EN, et al: Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Cell Genom. 2022;2:100179.","DOI":"10.1016\/j.xgen.2022.100179"},{"key":"3517_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad756","volume":"39","author":"M D\u00edaz-Gay","year":"2023","unstructured":"D\u00edaz-Gay M, Vangara R, Barnes M, Wang X, Islam SA, Vermes I, et al. Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment. Bioinformatics. 2023;39:btad756.","journal-title":"Bioinformatics"},{"key":"3517_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s43018-020-0027-5","volume":"1","author":"A Degasperi","year":"2020","unstructured":"Degasperi A, Amarante TD, Czarnecki J, Shooter S, Zou X, Glodzik D, et al. A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies. Nat Cancer. 2020;1:249\u201363.","journal-title":"Nat Cancer"},{"key":"3517_CR21","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1158\/1078-0432.CCR-22-2861","volume":"29","author":"PA Roelofs","year":"2023","unstructured":"Roelofs PA, Martens JW, Harris RS, Span PN. Clinical implications of APOBEC3-mediated mutagenesis in breast cancer. Clin Cancer Res. 2023;29:1658\u201369.","journal-title":"Clin Cancer Res"},{"key":"3517_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5677-2","volume":"19","author":"A Van Hoeck","year":"2019","unstructured":"Van Hoeck A, Tjoonk NH, van Boxtel R, Cuppen E. Portrait of a cancer: mutational signature analyses for cancer diagnostics. BMC Cancer. 2019;19:1\u201314.","journal-title":"BMC Cancer"},{"key":"3517_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41586-022-04972-y","volume":"607","author":"M Petljak","year":"2022","unstructured":"Petljak M, Dananberg A, Chu K, Bergstrom EN, Striepen J, von Morgen P, et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature. 2022;607:799\u2013807.","journal-title":"Nature"},{"key":"3517_CR24","doi-asserted-by":"crossref","unstructured":"Gupta A, Gazzo A, Selenica P, Safonov A, Pareja F, da Silva EM, et al. APOBEC3 mutagenesis drives therapy resistance in breast cancer. Nat Genet. 2025;57:1452\u201362.","DOI":"10.1038\/s41588-025-02187-1"},{"key":"3517_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-016-1042-9","volume":"17","author":"N Kanu","year":"2016","unstructured":"Kanu N, Cerone MA, Goh G, Zalmas L-P, Bartkova J, Dietzen M, et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol. 2016;17:1\u201315.","journal-title":"Genome Biol"},{"key":"3517_CR26","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"3517_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54223-z","volume":"15","author":"AB Silveira","year":"2024","unstructured":"Silveira AB, Houy A, Ganier O, \u00d6zemek B, Vanhuele S, Vincent-Salomon A, et al. Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes. Nat Commun. 2024;15:9864.","journal-title":"Nat Commun"},{"key":"3517_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-020-00781-y","volume":"12","author":"M-J Shi","year":"2020","unstructured":"Shi M-J, Meng X-Y, Fontugne J, Chen C-L, Radvanyi F, Bernard-Pierrot I. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Med. 2020;12:1\u201320.","journal-title":"Genome Med"},{"key":"3517_CR29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1158\/1078-0432.CCR-22-2270","volume":"29","author":"S Sivakumar","year":"2023","unstructured":"Sivakumar S, Jin DX, Rathod R, Ross J, Cantley LC, Scaltriti M, et al. Genetic heterogeneity and tissue-specific patterns of tumors with multiple PIK3CA mutations. Clin Cancer Res. 2023;29:1125\u201336.","journal-title":"Clin Cancer Res"},{"key":"3517_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade9120","volume":"9","author":"DJ Hsu","year":"2023","unstructured":"Hsu DJ, Gao J, Yamaguchi N, Pinzaru A, Wu Q, Mandayam N, et al. Arginine limitation drives a directed codon-dependent DNA sequence evolution response in colorectal cancer cells. Sci Adv. 2023;9:eade9120.","journal-title":"Sci Adv"},{"key":"3517_CR31","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.3390\/cancers13246274","volume":"13","author":"DD Nelakurti","year":"2021","unstructured":"Nelakurti DD, Rossetti T, Husbands AY, Petreaca RC. Arginine depletion in Human cancers. Cancers. 2021;13:6274.","journal-title":"Cancers"},{"key":"3517_CR32","doi-asserted-by":"publisher","first-page":"e0183273","DOI":"10.1371\/journal.pone.0183273","volume":"12","author":"ZA Szpiech","year":"2017","unstructured":"Szpiech ZA, Strauli NB, White KA, Ruiz DG, Jacobson MP, Barber DL, et al. Prominent features of the amino acid mutation landscape in cancer. PLoS One. 2017;12:e0183273.","journal-title":"PLoS One"},{"key":"3517_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/biom7030049","volume":"7","author":"V Tsuber","year":"2017","unstructured":"Tsuber V, Kadamov Y, Brautigam L, Warpman Berglund U, Helleday T. Mutations in cancer cause gain of cysteine, histidine, and tryptophan at the expense of a net loss of arginine on the proteome level. Biomolecules. 2017;7:49.","journal-title":"Biomolecules"},{"key":"3517_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw2872","volume":"364","author":"R Buisson","year":"2019","unstructured":"Buisson R, Langenbucher A, Bowen D, Kwan EE, Benes CH, Zou L, et al. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science. 2019;364:eaaw2872.","journal-title":"Science"},{"key":"3517_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt.3391","volume":"34","author":"MT Chang","year":"2016","unstructured":"Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34:155\u201363.","journal-title":"Nat Biotechnol"},{"key":"3517_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","volume":"8","author":"MT Chang","year":"2018","unstructured":"Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MT, Jonsson P, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 2018;8:174\u201383.","journal-title":"Cancer Discov"},{"key":"3517_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41588-023-01592-8","volume":"56","author":"DR Caswell","year":"2024","unstructured":"Caswell DR, Gui P, Mayekar MK, Law EK, Pich O, Bailey C, et al. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Nat Genet. 2024;56:60\u201373.","journal-title":"Nat Genet"},{"key":"3517_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41588-022-01196-8","volume":"54","author":"M Petljak","year":"2022","unstructured":"Petljak M, Green AM, Maciejowski J, Weitzman MD. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer. Nat Genet. 2022;54:1599\u2013608.","journal-title":"Nat Genet"},{"key":"3517_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/molbev\/mst195","volume":"31","author":"V Caval","year":"2014","unstructured":"Caval V, Suspene R, Vartanian J-P, Wain-Hobson S. Orthologous mammalian APOBEC3A cytidine deaminases hypermutate nuclear DNA. Mol Biol Evolut. 2014;31:330\u201340.","journal-title":"Mol Biol Evolut"},{"key":"3517_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2148-12-71","volume":"12","author":"C M\u00fcnk","year":"2012","unstructured":"M\u00fcnk C, Willemsen A, Bravo IG. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evolut Biol. 2012;12:1\u201316.","journal-title":"BMC Evolut Biol"},{"key":"3517_CR41","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1093\/nar\/gki524","volume":"33","author":"Y Zhang","year":"2005","unstructured":"Zhang Y. Skolnick J: TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res. 2005;33:2302\u20139.","journal-title":"Nucleic Acids Res"},{"key":"3517_CR42","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.4049\/jimmunol.1501504","volume":"195","author":"S Stavrou","year":"2015","unstructured":"Stavrou S, Ross SR. APOBEC3 proteins in viral immunity. J Immunol. 2015;195:4565\u201370.","journal-title":"J Immunol"},{"key":"3517_CR43","doi-asserted-by":"publisher","first-page":"W521","DOI":"10.1093\/nar\/gkae241","volume":"52","author":"F Madeira","year":"2024","unstructured":"Madeira F, Madhusoodanan N, Lee J, Eusebi A, Niewielska A, Tivey AR, et al. The EMBL-EBI Job Dispatcher sequence analysis tools framework in 2024. Nucleic Acids Res. 2024;52:W521\u20135.","journal-title":"Nucleic Acids Res"},{"key":"3517_CR44","doi-asserted-by":"publisher","first-page":"W320","DOI":"10.1093\/nar\/gku316","volume":"42","author":"X Robert","year":"2014","unstructured":"Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 2014;42:W320\u20134.","journal-title":"Nucleic Acids Res"},{"key":"3517_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45909-5","volume":"15","author":"A Sanchez","year":"2024","unstructured":"Sanchez A, Ortega P, Sakhtemani R, Manjunath L, Oh S, Bournique E, et al. Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes. Nat Commun. 2024;15:2370.","journal-title":"Nat Commun"},{"key":"3517_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46231-w","volume":"15","author":"Y Butt","year":"2024","unstructured":"Butt Y, Sakhtemani R, Mohamad-Ramshan R, Lawrence MS, Bhagwat AS. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations. Nat Commun. 2024;15:2369.","journal-title":"Nat Commun"},{"key":"3517_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 2023;32:e4792.","journal-title":"Protein Sci"},{"key":"3517_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nsmb.3344","volume":"24","author":"K Shi","year":"2017","unstructured":"Shi K, Carpenter MA, Banerjee S, Shaban NM, Kurahashi K, Salamango DJ, et al. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat Struct Mol Biol. 2017;24:131\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"3517_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15024","volume":"8","author":"T Kouno","year":"2017","unstructured":"Kouno T, Silvas TV, Hilbert BJ, Shandilya SM, Bohn MF, Kelch BA, et al. Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity. Nat Commun. 2017;8:15024.","journal-title":"Nat Commun"},{"key":"3517_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1476-5810.2006.00098.x","volume":"4","author":"R Uyama","year":"2006","unstructured":"Uyama R, Nakagawa T, Hong SH, Mochizuki M, Nishimura R, Sasaki N. Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. Vet Comp Oncol. 2006;4:104\u201313.","journal-title":"Vet Comp Oncol"},{"key":"3517_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.rvsc.2005.07.011","volume":"80","author":"T Nakagawa","year":"2006","unstructured":"Nakagawa T, Watanabe M, Ohashi E, Uyama R, Takauji S, Mochizuki M, et al. Cyclopedic protein expression analysis of cultured canine mammary gland adenocarcinoma cells from six tumours. Res Vet Sci. 2006;80:317\u201323.","journal-title":"Res Vet Sci"},{"key":"3517_CR52","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.rvsc.2010.11.016","volume":"91","author":"M Michishita","year":"2011","unstructured":"Michishita M, Akiyoshi R, Yoshimura H, Katsumoto T, Ichikawa H, Ohkusu-Tsukada K, et al. Characterization of spheres derived from canine mammary gland adenocarcinoma cell lines. Res Vet Sci. 2011;91:254\u201360.","journal-title":"Res Vet Sci"},{"key":"3517_CR53","doi-asserted-by":"crossref","unstructured":"Kim A-I, Oh JH, Cho J-Y: QSOX2 Upregulated in triple-negative breast cancer exacerbates patient prognosis by stabilizing integrin \u03b21. Heliyon. 2024;10:e27148.","DOI":"10.1016\/j.heliyon.2024.e27148"},{"key":"3517_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52671-1","volume":"15","author":"H Yang","year":"2024","unstructured":"Yang H, Pacheco J, Kim K, Bokani A, Ito F, Ebrahimi D, et al. Molecular mechanism for regulating APOBEC3G DNA editing function by the non-catalytic domain. Nat Commun. 2024;15:8773.","journal-title":"Nat Commun"},{"key":"3517_CR55","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/0008-5472.CAN-22-2912","volume":"83","author":"W Liu","year":"2023","unstructured":"Liu W, Newhall KP, Khani F, Barlow L, Nguyen D, Gu L, et al. The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer. Cancer Res. 2023;83:506\u201320.","journal-title":"Cancer Res"},{"key":"3517_CR56","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat methods. 2012;9:671\u20135.","journal-title":"Nat methods"},{"key":"3517_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52148-7","volume":"14","author":"S Di Cosimo","year":"2024","unstructured":"Di Cosimo S, Pizzamiglio S, Ciniselli CM, Duroni V, Cappelletti V, De Cecco L, et al. A gene expression-based classifier for HER2-low breast cancer. Sci Rep. 2024;14:2628.","journal-title":"Sci Rep"},{"key":"3517_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.18632\/oncotarget.28680","volume":"16","author":"WL Hensing","year":"2025","unstructured":"Hensing WL, Podany EL, Sears JJ, Tapiavala S, Davis AA. Evolving concepts in HER2-low breast cancer: genomic insights, definitions, and treatment paradigms. Oncotarget. 2025;16:11.","journal-title":"Oncotarget"},{"key":"3517_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88394-6","volume":"15","author":"ME Lacruz","year":"2025","unstructured":"Lacruz ME, Thies S, Schmidt-Pokrzywniak A, Wittenberg I, Engler T, Reinwald F, et al. Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer. Sci Rep. 2025;15:4584.","journal-title":"Sci Rep"},{"key":"3517_CR60","doi-asserted-by":"crossref","unstructured":"Fusco N, Viale G: The \u201clows\u201d: Update on ER-low and HER2-low breast cancer. Breast. 2024;78:103831.","DOI":"10.1016\/j.breast.2024.103831"},{"key":"3517_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57419-z","volume":"16","author":"L Hohmann","year":"2025","unstructured":"Hohmann L, Sigurjonsdottir K, Campos AB, Nacer DF, Veerla S, Rosengren F, et al. Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer. Nat Commun. 2025;16:2208.","journal-title":"Nat Commun"},{"key":"3517_CR62","doi-asserted-by":"crossref","unstructured":"Thennavan A, Beca F, Xia Y, Garcia-Recio S, Allison K, Collins LC, et al. Molecular analysis of TCGA breast cancer histologic types. Cell Genom. 2021;1:100067.","DOI":"10.1016\/j.xgen.2021.100067"},{"key":"3517_CR63","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1172\/JCI130323","volume":"130","author":"S Garcia-Recio","year":"2020","unstructured":"Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J Clin Investig. 2020;130:4871\u201387.","journal-title":"J Clin Investig"},{"key":"3517_CR64","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3390\/ani11072079","volume":"11","author":"S-H Kim","year":"2021","unstructured":"Kim S-H, Seung B-J, Cho S-H, Lim H-Y, Bae M-K, Sur J-H. Dysregulation of PI3K\/Akt\/PTEN pathway in canine mammary tumor. Animals. 2021;11:2079.","journal-title":"Animals"},{"key":"3517_CR65","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-022-04618-z","volume":"604","author":"A Cagan","year":"2022","unstructured":"Cagan A, Baez-Ortega A, Brzozowska N, Abascal F, Coorens TH, Sanders MA, et al. Somatic mutation rates scale with lifespan across mammals. Nature. 2022;604:517\u201324.","journal-title":"Nature"},{"key":"3517_CR66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41416-024-02658-y","volume":"131","author":"M Braun","year":"2024","unstructured":"Braun M, Piasecka D, Sadej R, Romanska HM. FGFR4-driven plasticity in breast cancer progression and resistance to therapy. Br J Cancer. 2024;131:11\u201322.","journal-title":"Br J Cancer"},{"key":"3517_CR67","doi-asserted-by":"publisher","first-page":"107590","DOI":"10.1016\/j.pharmthera.2020.107590","volume":"214","author":"KM Levine","year":"2020","unstructured":"Levine KM, Ding K, Chen L, Oesterreich S. FGFR4: a promising therapeutic target for breast cancer and other solid tumors. Pharmacol Therapeut. 2020;214:107590.","journal-title":"Pharmacol Therapeut"},{"key":"3517_CR68","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/bioinformatics\/btv693","volume":"32","author":"DM Gendoo","year":"2016","unstructured":"Gendoo DM, Ratanasirigulchai N, Schr\u00f6der MS, Par\u00e9 L, Parker JS, Prat A, et al. Genefu: an R\/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics. 2016;32:1097\u20139.","journal-title":"Bioinformatics"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03517-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03517-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03517-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:57:31Z","timestamp":1792166251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03517-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11,5]]}},"alternative-id":["3517"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03517-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. For human data, publicly available datasets (TCGA breast cancer clinical, WES, and RNA-seq data) were analysed in this study. Since these data were obtained from open-access databases where all participant information is de-identified, further institutional review board (IRB) approval was waived. Original data collection by the TCGA project was conducted with appropriate ethics committee approval and informed consent obtained from all participants. For canine samples, the whole-exome sequencing (WES) dataset of canine mammary tumours and matching adjacent normal tissues (205 pairs from Yonsei University and CDRC) was analysed. The original sample collection and data generation were conducted with informed owner consent and under the ethical approval of the Institutional Animal Care and Use Committees (IACUC) of Konkuk University (Approval Nos. KU16106, KU17162) and Seoul National University (Approval No. IACUC# SNU-170602-1). All procedures were performed in accordance with the relevant institutional guidelines and ethical regulations for animal research. The use of all established canine and human cell lines in this study was conducted in accordance with the institutional ethical guidelines for established cell lines, and did not require specific ethical approval.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}